Safety of very tight blood glucose control in type 2 diabetesBMJ 2008; 336 doi: https://doi.org/10.1136/bmj.39499.514410.80 (Published 28 February 2008) Cite this as: BMJ 2008;336:458
- Philip Home, professor of diabetes medicine
- 1School of Clinical Medical Sciences, Newcastle University, Newcastle NE2 4HH
On 8 February 2008, the glucose lowering arm of a large ongoing randomised controlled trial (ACCORD) of people with type 2 diabetes at high risk of cardiovascular events was stopped 18 months early because of concerns about safety. Intensively lowering blood glucose to a target below current recommendations (glycated haemoglobin (HbA1c) <6.0%) increased the risk of death compared with a less intensive standard treatment strategy (HbA1c 7.0-7.9%). This amounted to an excess of deaths of 3/1000 participant years on a background control rate of 10/1000 participant years.1
So what do these findings mean for clinical practice? Several evidence based or consensus guidelines in recent years have recommended target values of HbA1c <6.5% or <7.0%.2 3 Targets of this kind, however, are rarely tested in clinical trials, which usually compare strategies of different intensity rather than treatment to different targets. Accordingly, the evidence used in target setting is usually secondary—it comes from findings embedded within the results of such treatment trials. This evidence is often supplemented by data from observational studies and within study analyses.
For type …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial